Novel Targets for the Treatment of Melanoma

被引:18
作者
Ambrosi, Lara [1 ]
Khan, Shaheer [2 ]
Carvajal, Richard D. [2 ]
Yang, Jessica [2 ]
机构
[1] Stony Brook SOM, 101 Nicholls Rd, Stony Brook, NY 11794 USA
[2] Columbia Univ, Med Ctr, Div Hematol Oncol, 177 Ft Washington Ave,MHB 6GN-435, New York, NY 10032 USA
关键词
Melanoma; Immunotherapy; Checkpoint inhibitors; CTLA-4; PD-1; PD-L1; Targeted therapy; MEK inhibitor; BRAF inhibitor; Oncolytic therapy; TUMOR-INFILTRATING LYMPHOCYTES; LONG-TERM SURVIVAL; ADOPTIVE CELL THERAPY; OPEN-LABEL PHASE-3; CD8(+) T-CELLS; METASTATIC MELANOMA; IMMUNE CHECKPOINT; ANTITUMOR-ACTIVITY; KINASE INHIBITOR; BRAF INHIBITION;
D O I
10.1007/s11912-019-0849-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of Review In this article, we will briefly review the current treatment landscape for metastatic melanoma and provide a comprehensive update on emerging novel treatment strategies. Recent Findings Over the past decade, remarkable advances in immunotherapy and targeted therapy have greatly improved outcomes for patients with advanced melanoma. Although a subset of patients is able to achieve durable responses, the majority experience eventual disease progression on existing therapies. Trials evaluating novel combinatorial strategies, checkpoint inhibitors, immune agonists, T cell-based therapies, intratumoral agents, and others are ongoing. While strides have been made in the treatment of advanced melanoma, further research is needed to identify alternative immune and molecular targets in order to overcome resistance and achieve better clinical outcomes.
引用
收藏
页数:16
相关论文
共 152 条
  • [101] TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects
    Lu, Hailing
    [J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [102] Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
    Lu, Yong-Chen
    Parker, Linda L.
    Lu, Tangying
    Zheng, Zhili
    Toomey, Mary Ann
    White, Donald E.
    Yao, Xin
    Li, Yong F.
    Robbins, Paul F.
    Feldman, Steven A.
    van der Bruggen, Pierre
    Klebanoff, Christopher A.
    Goff, Stephanie L.
    Sherry, Richard M.
    Kammula, Udai S.
    Yang, James C.
    Rosenberg, Steven A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (29) : 3322 - +
  • [103] Next generation of immune checkpoint therapy in cancer: new developments and challenges
    Marin-Acevedo, Julian A.
    Dholaria, Bhagirathbhai
    Soyano, Aixa E.
    Knutson, Keith L.
    Chumsri, Saranya
    Lou, Yanyan
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [104] Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
    Matsui, Junji
    Funahashi, Yasuhiro
    Uenaka, Toshimitsu
    Watanabe, Tatsuo
    Tsuruoka, Akihiko
    Asada, Makoto
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (17) : 5459 - 5465
  • [105] E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
    Matsui, Junji
    Yamamoto, Yuji
    Funahashi, Yasuhiro
    Tsuruoka, Akihiko
    Watanabe, Tatsuo
    Wakabayashi, Toshiaki
    Uenaka, Toshimitsu
    Asada, Makoto
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2008, 122 (03) : 664 - 671
  • [106] Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses
    Mellor, AL
    Keskin, DB
    Johnson, T
    Chandler, P
    Munn, DH
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (08) : 3771 - 3776
  • [107] Safety, pharmacokinetics and efficacy of IMCgp100, a first-in-class soluble TCR-antiCD3 bispecific t cell redirector with solid tumour activity: Results from the FIH study in melanoma
    Middleton, Mark R.
    Steven, Neil Matthew
    Evans, Thomas Jeff
    Infante, Jeffrey R.
    Sznol, Mario
    Mulatero, Clive
    Hamid, Omid
    Shoushtari, Alexander Noor
    Shingler, William
    Johnson, Andy
    Patel, Sanjay
    Parker, Debbie
    Krige, David
    McAlpine, Cheryl
    Coughlin, Christina Marie
    Hassan, Namir J.
    Jakobsen, Bent K.
    Corrie, Philippa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [108] Atezolizumab (A) plus cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity.
    Miller, Wilson H.
    Kim, Tae Min
    Lee, Carrie B.
    Flaherty, Keith T.
    Reddy, Sunil
    Jamal, Rahima
    Chow, Laura Q.
    Rooney, Isabelle Anne
    Pitcher, Bethany
    Cha, Edward
    Infante, Jeffrey R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [109] Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
    Minucci, S
    Pelicci, PG
    [J]. NATURE REVIEWS CANCER, 2006, 6 (01) : 38 - 51
  • [110] Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
    Monney, L
    Sabatos, CA
    Gaglia, JL
    Ryu, A
    Waldner, H
    Chernova, T
    Manning, S
    Greenfield, EA
    Coyle, AJ
    Sobel, RA
    Freeman, GJ
    Kuchroo, VK
    [J]. NATURE, 2002, 415 (6871) : 536 - 541